Savara (SVRA) announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback